The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Johnson & Johnson has an expected revenue and earnings growth rate of 5% and 5.7%, respectively, for the current year

  80% confidence

• Medtronic has an expected earnings growth rate of 2.7% for the current year (ending April 2026)

  80% confidence

• Johnson & Johnson has an expected earnings growth rate of 5.7% for the current year

  80% confidence

• Zacks top stock-picking strategies soared with average gains of +48.4%, +50.2% and +56.7% per year since 2000

  80% confidence

• Regeneron Pharmaceuticals has an expected revenue growth rate of 4.9% for the current year

  80% confidence

• Eli Lilly has an expected revenue growth rate of 22.3% for the current year

  80% confidence

• Intuitive Surgical has an expected revenue growth rate of 14.3% for the current year

  80% confidence

• The Zacks Consensus Estimate for Eli Lilly current-year earnings has improved 0.7% over the last 30 days

  80% confidence

• Medtronic has an expected revenue and earnings growth rate of 7.5% and 2.7%, respectively, for the current year ending April 2026

  80% confidence

• AI fundamentally reshaped the medical landscape in 2024, revolutionizing diagnostics, treatment and operational efficiency

  80% confidence

• Eli Lilly has a Zacks Rank #1 (Strong Buy)

  80% confidence

• Zacks top stock-picking strategies have achieved average gains of +48.4%, +50.2% and +56.7% per year since 2000, compared to S&P 500's +7.7% average gain per year

  80% confidence

• Regeneron Pharmaceuticals has an expected earnings growth rate of -0.4% for the current year

  80% confidence

• The supercomputer will power an AI factory, a specialized computing infrastructure that manages the entire AI lifecycle from data ingestion and training to fine-tuning and high-volume inference.

  80% confidence

• Intuitive Surgical carries a Zacks Rank #2 (Buy)

  80% confidence

• Regeneron put up a decent performance in 2025 as revenues grew despite declining sales of its lead drug Eylea

  80% confidence

• Eli Lilly has a return on equity of 109.5% compared with the industry's ROE of 37% and the S&P 500's ROE of 17%

  80% confidence

• ISRG has an ROE of 15.1% compared with the industry's ROE of -18.7% and the S&P 500's ROE of 17%

  80% confidence

• The medical sector is one of the major adopters of artificial intelligence, which is currently being used to synthesize new compounds for drugs and create devices for more precise measurement and faster as well as more accurate diagnosis

  80% confidence

• Medtronic carries a Zacks Rank #2 (Buy)

  80% confidence

• Eli Lilly has an expected earnings growth rate of 41.3% for the current year

  80% confidence

• Eli Lilly has an expected revenue and earnings growth rate of 22.3% and 41.3%, respectively, for the current year

  80% confidence

• Hypertension presents a multi-billion-dollar opportunity as Medtronic ramps up for CMS coverage of Symplicity

  80% confidence

• Medtronic has an expected revenue growth rate of 7.5% for the current year (ending April 2026)

  80% confidence

• Intuitive Surgical has an expected revenue and earnings growth rate of 14.3% and 11.1%, respectively, for the current year

  80% confidence

• REGN has an ROE of 13.8% compared with the industry's ROE of -65.41% and the S&P 500's ROE of 17%

  80% confidence

• Johnson & Johnson has an expected revenue growth rate of 5% for the current year

  80% confidence

• The healthcare sector is generally defensive in nature with most stocks characterized as low-beta and dividend paying, but extensive use of AI has transformed several into potential high-growth providers

  80% confidence

• Johnson & Johnson carries a Zacks Rank #3 (Hold)

  80% confidence

• Eli Lilly currently sports a Zacks Rank #1 (Strong Buy)

  80% confidence